nach oben

Erschienen in:

01.02.2011 | Clinical trial

Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer

verfasst von: Takayuki Iwamoto, Giampaolo Bianchini, Yuan Qi, Massimo Cristofanilli, Anthony Lucci, Wendy A. Woodward, James M. Reuben, Junji Matsuoka, Yun Gong, Savitri Krishnamurthy, Vicente Valero, Gabriel N. Hortobagyi, Fredika Robertson, W. Fraser Symmans, Lajos Pusztai, Naoto T. Ueno

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

The goal of this study was to determine whether gene expression differences exist between inflammatory breast cancers (IBC) and T stage-matched non-IBC patients stratified by hormone receptor and HER2 status. We used Affymetrix GeneChips to analyze 82 tumor samples (25 T4d patients, and 57 T4a-c patients) of newly diagnosed breast cancers. Genes that were differentially expressed between the IBC and non-IBC specimens were identified using the t test, and differential expression of gene sets was assessed using gene set analysis. Three distinct clinical subtypes of IBC and non-IBC were compared: ER-positive/HER2-normal, HER2-amplified, and ER-negative/HER2-normal. When we compared expression data from all IBC with all non-IBC, we found no significant differences after adjusting for multiple testing. When IBC and non-IBC tumors were compared by clinical subtype, however, significant differences emerged. Complement and immune system-related pathways were overexpressed in ER-positive/HER2-normal IBC. Protein translation and mTOR signaling were overexpressed in HER2-amplified IBC. Apoptosis-, neural-, and lipid metabolism-related pathways were overexpressed in ER-negative/HER2-normal IBC compared with non-IBC of the same receptor phenotype. In this T stage-matched case–control study, the survival curves of patients with IBC and non-IBC were similar for all three clinical subtypes. IBC tumors can be divided into molecular and clinical subtypes similar to those of non-IBC. Clinical subtypes of IBC show molecular differences compared with similar subtypes of non-IBC.

Nur mit Berechtigung zugänglich

Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL (2002) Revision of the American joint committee on cancer staging system for breast cancer. J Clin Oncol 20(17):3628–3636CrossRefPubMed

Levine PH, Steinhorn SC, Ries LG, Aron JL (1985) Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (seer) program. J Natl Cancer Inst 74(2):291–297PubMed

Cristofanilli M, Buzdar AU, Hortobagyi GN (2003) Update on the management of inflammatory breast cancer. Oncologist 8(2):141–148CrossRefPubMed

Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R (2004) Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 10(20):6789–6795. doi:10.1158/1078-0432.CCR-04-0306 CrossRefPubMed

Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Cervera N, Tarpin C, Nguyen C, Xerri L, Houlgatte R, Jacquemier J, Viens P, Birnbaum D (2005) Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 65(6):2170–2178. doi:10.1158/0008-5472.CAN-04-4115 CrossRefPubMed

Nguyen DM, Sam K, Tsimelzon A, Li X, Wong H, Mohsin S, Clark GM, Hilsenbeck SG, Elledge RM, Allred DC, O’Connell P, Chang JC (2006) Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res 12(17):5047–5054. doi:10.1158/1078-0432.CCR-05-2248 CrossRefPubMed

Van Laere S, Van der Auwera I, Van den Eynden G, Van Hummelen P, van Dam P, Van Marck E, Vermeulen PB, Dirix L (2007) Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using affymetrix-based genome-wide gene-expression analysis. Br J Cancer 97(8):1165–1174. doi:10.1038/sj.bjc.6603967 CrossRefPubMed

Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gomez HL, Hortobagyi GN, Pusztai L (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24(26):4236–4244. doi:10.1200/JCO.2006.05.6861 CrossRefPubMed

Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE Jr, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N, Hortobagyi GN, Pusztai L, Symmans WF (2007) Determination of oestrogen-receptor status and Erbb2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 8(3):203–211. doi:10.1016/S1470-2045(07)70042-6 CrossRefPubMed

10.

Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160–1167. doi:10.1200/JCO.2008.18.1370 CrossRefPubMed

11.

Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98(9):5116–5121. doi:10.1073/pnas.091062498 CrossRefPubMed

12.

Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545–15550. doi:10.1073/pnas.0506580102 CrossRefPubMed

13.

Van Laere S, Van der Auwera I, Van den Eynden GG, Fox SB, Bianchi F, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY (2005) Distinct molecular signature of inflammatory breast cancer by cdna microarray analysis. Breast Cancer Res Treat 93(3):237–246. doi:10.1007/s10549-005-5157-z CrossRefPubMed

14.

Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B, Camerlo J, Tagett R, Tarpin C, Houvenaeghel G, Nguyen C, Maraninchi D, Jacquemier J, Houlgatte R, Birnbaum D, Viens P (2004) Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 64(23):8558–8565. doi:10.1158/0008-5472.CAN-04-2696 CrossRefPubMed

15.

DiMeo TA, Anderson K, Phadke P, Feng C, Perou CM, Naber S, Kuperwasser C (2009) A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res 69(13):5364–5373. doi:10.1158/0008-5472.CAN-08-4135 CrossRefPubMed

16.

Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11(3):259–273. doi:10.1016/j.ccr.2007.01.013 CrossRefPubMed

17.

Jiang Z, Gentleman R (2007) Extensions to gene set enrichment. Bioinformatics 23(3):306–313. doi:10.1093/bioinformatics/btl599 CrossRefPubMed

18.

Efron B, Tishirani R (2007) On testing the significance of sets of genes. Ann Appl Stat 1(1):107–129CrossRef

19.

Silvera D, Arju R, Darvishian F, Levine PH, Zolfaghari L, Goldberg J, Hochman T, Formenti SC, Schneider RJ (2009) Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancer. Nat Cell Biol 11(7):903–908. doi:10.1038/ncb1900 CrossRefPubMed

20.

Forozan F, Veldman R, Ammerman CA, Parsa NZ, Kallioniemi A, Kallioniemi OP, Ethier SP (1999) Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer 81(8):1328–1334. doi:10.1038/sj.bjc.6695007 CrossRefPubMed

21.

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672. doi:10.1056/NEJMoa052306 CrossRefPubMed

22.

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684. doi:10.1056/NEJMoa052122 CrossRefPubMed

23.

Van Pelt AE, Mohsin S, Elledge RM, Hilsenbeck SG, Gutierrez MC, Lucci A Jr, Kalidas M, Granchi T, Scott BG, Allred DC, Chang JC (2003) Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer 4(5):348–353CrossRefPubMed

24.

Hurley J, Doliny P, Reis I, Silva O, Gomez-Fernandez C, Velez P, Pauletti G, Powell JE, Pegram MD, Slamon DJ (2006) Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 24(12):1831–1838. doi:10.1200/JCO.2005.02.8886 CrossRefPubMed

25.

Limentani SA, Brufsky AM, Erban JK, Jahanzeb M, Lewis D (2007) Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol 25(10):1232–1238. doi:10.1200/JCO.2005.05.3306 CrossRefPubMed

26.

Yamauchi H, Cristofanilli M, Nakamura S, Hortobagyi GN, Ueno NT (2009) Molecular targets for treatment of inflammatory breast cancer. Nat Rev Clin Oncol 6(7):387–394. doi:10.1038/nrclinonc.2009.73 CrossRefPubMed

27.

Kaufman B, Trudeau M, Awada A, Blackwell K, Bachelot T, Salazar V, DeSilvio M, Westlund R, Zaks T, Spector N, Johnston S (2009) Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol 10(6):581–588. doi:10.1016/S1470-2045(09)70087-7 CrossRefPubMed

28.

Gelderman KA, Tomlinson S, Ross GD, Gorter A (2004) Complement function in mab-mediated cancer immunotherapy. Trends Immunol 25(3):158–164. doi:10.1016/j.it.2004.01.008S CrossRefPubMed

29.

Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3(5):269–280. doi:10.1038/ncponc0509 CrossRefPubMed

30.

Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML (2004) Randomized phase ii study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22(5):909–918. doi:10.1200/JCO.2004.08.185 CrossRefPubMed

31.

Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O’Reilly T, Natt F, Hall J, Lane HA, Thomas G (2005) The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120(6):747–759. doi:10.1016/j.cell.2004.12.040 CrossRefPubMed

32.

Mita MM, Mita AC, Chu QS, Rowinsky EK, Fetterly GJ, Goldston M, Patnaik A, Mathews L, Ricart AD, Mays T, Knowles H, Rivera VM, Kreisberg J, Bedrosian CL, Tolcher AW (2008) Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 26(3):361–367. doi:10.1200/JCO.2007.12.0345 CrossRefPubMed

33.

Drell TL, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F (2003) Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 80(1):63–70. doi:10.1023/A:1024491219366 CrossRefPubMed

34.

Crawford KW, Bowen WD (2002) Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res 62(1):313–322PubMed

35.

Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP (1998) Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95(15):8806–8811CrossRefPubMed

Titel: Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer
verfasst von: Takayuki Iwamoto
Giampaolo Bianchini
Yuan Qi
Massimo Cristofanilli
Anthony Lucci
Wendy A. Woodward
James M. Reuben
Junji Matsuoka
Yun Gong
Savitri Krishnamurthy
Vicente Valero
Gabriel N. Hortobagyi
Fredika Robertson
W. Fraser Symmans
Lajos Pusztai
Naoto T. Ueno
Publikationsdatum: 01.02.2011
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2011
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-1280-6

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2011

Gene expression array testing of FFPE archival breast tumor samples: an optimized protocol for WG-DASL® sample preparation

Endoscopic breast surgery: where are we now and what might the future hold for video-assisted breast surgery?

Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies

Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer

Tumor–stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients

Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie